Novo Nordisk invests $225 million in new Danish NovoSeven manufacturing plant

4 May 2015

Shares of Danish diabetes care giant Novo Nordisk (NOV: N) saw its shares edge up 1.35% this morning, after it said it is investing 1.5 billion Danish kroner ($225 million) in a new 7,500 m2 facility in Kalundborg, Denmark. The facility will produce active pharmaceutical ingredients for NovoSeven (recombinant Factor VIIa) and future products for treating hemophilia.

The investment is estimated to create 100 new production and engineering jobs in Kalundborg, where Novo Nordisk currently employs more than 2,800people. NovoSeven generated sales of 2.65 billion kroner, a rise of 18%, in the first quarter of 2015.

"The investment in Kalundborg underscores our long-term ambition to create and maintain jobs in Denmark. This year alone we expect Novo Nordisk will create about 250 new jobs in Kalundborg, and we are always on the lookout for capable and highly skilled employees," said Henrik Wulff, executive vice president, product supply, Novo Nordisk.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK